Modern Psychopharmacology: Integrating Molecular Modeling, Omics Technologies, Translational Models, and Evidence-Based Clinical Studies.

Vollständiger Abstract

Worum geht es in dieser Arbeit?

This article summarizes the outcomes of three symposia on psychopharmacology held within the framework of the XIII All-Russian Conference with International Participation “Current Issues in Preclinical and Clinical Research of Medicinal Products and Clinical Trials of Medical Devices” (St. Petersburg, April 23–24, 2026). The advancement of modern psychopharmacology requires the implementation of personalized approaches, the application of molecular modeling and computational biology methods, and the integration of pharmacogenetic, pharmacoepigenomic, and multi-omics data into drug development and efficacy assessment processes. The symposium participants identified the following priority directions for the development of contemporary psychopharmacology: (1) implementation of integrated in silico pipelines throughout all stages of drug development; (2) broader application of molecular modeling approaches for the design of innovative therapeutic agents and targeted drug delivery systems; (3) development of standardized translational models with high reproducibility and predictive value for preclinical research; and (4) integration of pharmacogenomic, pharmacoepigenomic, and multi-omics methodologies into the design and conduct of clinical studies. The major challenges facing modern psychopharmacology include: (1) further improvement of the regulatory and methodological framework governing the use of advanced digital and computational technologies, including artificial intelligence, in the development of medicinal products and medical devices; (2) standardization and validation of in silico modeling data, as well as implementation of pharmacogenetic approaches in psychiatric and addiction medicine practice; (3) development of interdisciplinary educational programs at the intersection of medicine, biology, bioinformatics, cheminformatics, and information technologies; and (4) establishment of multidisciplinary research consortia. In conclusion, the future development of psychopharmacology depends on the systematic integration of fundamental biomedical research, omics technologies, computational approaches, translational models, and high-quality clinical investigations. The implementation of such integrative projects will facilitate the development of innovative therapeutic agents and promote the advancement of personalized psychiatry and addiction medicine.